Michael Koslowski
Algemeen Directeur bij Kling Biotherapeutics BV
Actieve functies van Michael Koslowski
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Kling Biotherapeutics BV
 Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Algemeen Directeur | 12-12-2022 | - |
Loopbaan van Michael Koslowski
Eerdere bekende functies van Michael Koslowski
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Michael Koslowski
| Universität des Saarlandes | Undergraduate Degree |
| Universität zu Köln | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 3 |
| Nederland | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Kling Biotherapeutics BV
Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Michael Koslowski
- Ervaring
